CRDF Key Statistics, Chart & Performance
The current stock price of CRDF is 2.95 USD. In the past month the price increased by 29.39%. In the past year, price decreased by -37.23%.
CRDF Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.43 | 407.98B | ||
| AMGN | AMGEN INC | 15.07 | 177.50B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.49 | 116.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.34 | 82.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 782 | 52.69B | ||
| INSM | INSMED INC | N/A | 37.61B | ||
| NTRA | NATERA INC | N/A | 31.92B | ||
| BIIB | BIOGEN INC | 10.56 | 25.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.06 | 21.65B | ||
| INCY | INCYTE CORP | 15.47 | 19.49B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About CRDF
Company Profile
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 32 full-time employees. The company went IPO on 2004-07-27. The company is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. The company is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. The company has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Company Info
CARDIFF ONCOLOGY INC
11055 Flintkote Ave
San Diego CALIFORNIA 92121 US
CEO: Mark Erlander
Employees: 33
Phone: 18589527570
CARDIFF ONCOLOGY INC / CRDF FAQ
What does CRDF do?
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company is headquartered in San Diego, California and currently employs 32 full-time employees. The company went IPO on 2004-07-27. The company is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. The company is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. The company has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Can you provide the latest stock price for CARDIFF ONCOLOGY INC?
The current stock price of CRDF is 2.95 USD. The price decreased by -6.94% in the last trading session.
What is the dividend status of CARDIFF ONCOLOGY INC?
CRDF does not pay a dividend.
How is the ChartMill rating for CARDIFF ONCOLOGY INC?
CRDF has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for CARDIFF ONCOLOGY INC?
CARDIFF ONCOLOGY INC (CRDF) currently has 33 employees.
Can you provide the market cap for CARDIFF ONCOLOGY INC?
CARDIFF ONCOLOGY INC (CRDF) has a market capitalization of 198.71M USD. This makes CRDF a Micro Cap stock.
When does CARDIFF ONCOLOGY INC (CRDF) report earnings?
CARDIFF ONCOLOGY INC (CRDF) will report earnings on 2026-02-25, after the market close.
CRDF Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CRDF. When comparing the yearly performance of all stocks, CRDF is a bad performer in the overall market: 62.99% of all stocks are doing better.
CRDF Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CRDF. While CRDF seems to be doing ok healthwise, there are quite some concerns on its profitability.
CRDF Financial Highlights
Over the last trailing twelve months CRDF reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 14.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.42% | ||
| ROE | -103.82% | ||
| Debt/Equity | 0 |
CRDF Forecast & Estimates
14 analysts have analysed CRDF and the average price target is 10.63 USD. This implies a price increase of 260.17% is expected in the next year compared to the current price of 2.95.
For the next year, analysts expect an EPS growth of 17.45% and a revenue growth -24.43% for CRDF